A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma. Phase II Studie des tumorspezifischen Antikörpers F16IL2 in Kombination mit Paclitaxel bei Patienten mit metastatischen Merkelzellkarzinom To compare the efficacy of F16IL2 in combination with paclitaxel vs. paclitaxel monotherapy, in terms of overall survival rate at 12 months after beginning of study treatments, in patients with metast...

• Country None
• organs None
• Specialty None

A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions. Studio di fase II di applicazione intratumorale di L19IL2/L19TNF nei pazienti con melanoma in stadio clinico III o IV M1a con presenza di lesioni iniettabili cutanee e/o sottocutanee Efficacy of L19IL2/L19TNF-treated lesions measured as : Rate of patients with complete response (CR) of L19IL2/L19TNF-treated lesions at week 12 (day 85). Efficacia del L19IL2/L19TNF sulle lesi...

• Country None
• organs None
• Specialty None

A phase II study of L19IL2 injected directly into the tumor in patients with stage III/IV melanoma Rate of patients with complete response (CR) of L19IL2 treated metastases at week 12

• Country None
• organs None
• Specialty None

Study of Phase I/II of the combination of L19IL2 with Rituximab in Diffuse Large B-cell Lymphoma Phase I: 1) To assess the MTD and monitor the safety of L19IL2 in combination with Rituximab in patients with relapsed or refractory DLBCL and to describe DLT. 2) To define the RD of L19IL2 to be used...

• Country None
• organs None
• Specialty None

A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER Phase I: - Determination of maximum tolerated dose and recommended dose Phase II: - Investigation of the antitumor activity at the recommended dose in cancer patients (objective response rate)

• Country None
• organs None
• Specialty None

Study of the efficacy of intratumoral injections of L19IL2/L19TNF followed by surgery to prevent or retard appearance of new metastases Efficacy of L19IL2/L19TNF measured as recurrence-free survival (RFS) rate in the L19IL2/L19TNF plus surgery treatment group (Arm 1) versus surgery alone (Arm 2), assessed at 1 year after randomizatio...

• Country None
• organs None
• Specialty None

A multicenter, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 administered subcutaneously to patients with active rheumatoid arthritis receiving Methotrexate Mean change from baseline in DAS28-CRP between F8IL10 and placebo arms at week 9.

• Country None
• organs None
• Specialty None

A Phase I/II Dose Escalation study of the tumor-targeting L19-IL2 antibody-cytokine in combination with Dacarbazine for patients with metastatic melanoma Phase I: Maximum tolerated dose (MTD) and the recommended dose (RD) of L19IL2 for phase II when administered in combination with a fixed dose of DTIC. Phase II: Antitumor activity in terms of be...

• Country None
• organs None
• Specialty None

Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma Phase IIa part: - To establish the recommended dose (RD) of L19IL2 when administered in combination with a fixed dose of DTIC in patients with metastatic melanoma, the preliminary tolerability profil...

• Country None
• organs None
• Specialty None

A prospective non-randomized study of 131I-L19SIP Radioimmunotherapy (RIT) in combination with Whole Brain Radiation Therapy (WBRT) in patients with multiple brain metastases from solid tumors To evaluate the safety of the administration of radioimmunotherapy with 131I-L19SIP combined with whole brain radiation treatment (the standard treatment)and to determine the selective uptake of the s...

• Country None
• organs None
• Specialty None